About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Travere Therapeutics Launches "Play It Forward" Campaign to Celebrate the FSGS Community on Inaugural Awareness Day

By: via Business Wire

Grammy-winning producer and platinum recording artist joins forces with patient advocate and singer-songwriter to transform the invisible struggle of FSGS into a creative movement

New campaign aims to unite the FSGS community and inspire patients and caregivers to share their journeys

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the launch of a new awareness campaign, “Play It Forward,” to bring hope and encouragement to the focal segmental glomerulosclerosis (FSGS) community. FSGS is a rare kidney disease (RKD) affecting children and adults and a leading cause of kidney failure.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250610121537/en/

Brian Kennedy (right) and David Rush (left) unite their musical talents for the "Play It Forward" campaign, creating an uplifting anthem that transforms the often invisible struggle of FSGS into a creative expression of strength and solidarity.

Brian Kennedy (right) and David Rush (left) unite their musical talents for the "Play It Forward" campaign, creating an uplifting anthem that transforms the often invisible struggle of FSGS into a creative expression of strength and solidarity.

Launching on the first-ever FSGS Awareness Day, the campaign features a powerful anthem, written and produced by Grammy-winning musician Brian Kennedy and singer-songwriter, David Rush, both living with FSGS. The song celebrates the strength of the FSGS community coming together. The musicians invite the FSGS community to use the soundtrack to post their own creative and artistic expressions on social media, showcasing the unique talents of the community and the stories of individuals who are thriving beyond the limits of FSGS.

"When I received my FSGS diagnosis, it felt like the volume of my life was suddenly turned down. My studio became my sanctuary," said Brian Kennedy, a multi-Grammy-winning producer, songwriter, and pianist. "I'm proud to play it forward with music that helps others hear their own strength. Together, we're translating the invisible struggle of FSGS into creative expressions that everyone can witness, creating a soundtrack for solidarity."

"Every FSGS story has the power to make a meaningful difference in someone else's life," said David Rush, singer, songwriter, motivational speaker, FSGS advocate, and patient. "While living with FSGS may try to dim my light, my music replenishes my spirit – that's how I play it forward for others fighting FSGS. This campaign provides a platform for patients and their loved ones to share experiences that offer hope, guidance, and inspiration to others facing similar challenges."

The campaign launch also features a hero video featuring Kennedy and Rush discussing their FSGS journeys and documenting the creation of their anthem. By uniting with the FSGS community, the two artists turn isolation into connection, using their shared experiences to inspire and empower others living with FSGS.

"On FSGS Awareness Day and every day, we know that obstacles impede every step of the patient journey -- from diagnostic hurdles to an often-aggressive progression to kidney failure,” said Jula Inrig, M.D., chief medical officer at Travere Therapeutics. “We are proud to support the FSGS community in amplifying individual expressions of life and courage, and we're committed to transforming the challenges of FSGS into pathways of hope and healing."

To follow or participate in the campaign, search #PlayitForwardFSGS. Learn more at RKDandMe.com/PlayItForwardFSGS.

About FSGS

Focal segmental glomerulosclerosis (FSGS) is a rare proteinuric kidney disorder in children and adults that is estimated to affect more than 40,000 patients in the U.S., with similar prevalence in Europe. The disorder is defined by progressive scarring of the kidneys and often leads to kidney failure. FSGS is characterized by proteinuria, in which protein leaks into the urine due to a breakdown of the normal filtration mechanism in the kidney. Once in the urine, protein is toxic to other parts of the kidney, especially the tubules, and is believed to contribute to further disease progression. Other common symptoms include swelling in parts of the body, known as edema, as well as low blood albumin levels, abnormal lipid profiles and hypertension. There are currently no FDA-approved pharmacologic therapies for FSGS.

About Travere Therapeutics

At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.

"We are proud to support the FSGS community in amplifying individual expressions of life and courage, and we're committed to transforming the challenges of FSGS into pathways of hope and healing."

Contacts

More News

View More
Pfizer is Locking in New Growth Through a New Acquisition
Via MarketBeat
Topics Artificial Intelligence
Tickers MTSR PFE
Copper Giant Freeport Slumps but Analysts See 33% Upside
Via MarketBeat
Tickers FCX SCCO
The BYD Opportunity: Tesla-Like Growth at a Fraction of the Price
Via MarketBeat
Topics Electric Vehicles
Tickers BYDDY LI TSLA
3 Reasons CoreWeave Could Be the Hottest AI Stock in Q4
Via MarketBeat
Topics Artificial Intelligence
Tickers CRWV NVDA
Accenture: Undervalued GenAI Leader or Snake Eating its Own Tail?
Via MarketBeat
Tickers ACN IBM
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.